Wechselwirkungen · Imbruvica
IMBRUVICA 140 mg film-coated tablets IMBRUVICA 280 mg film-coated tablets IMBRUVICA 420 mg film-coated tablets IMBRUVICA 560 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52–53
HOS-131647 · Präparat HOS-097103
52 Agents that may have their plasma concentrations altered by ibrutinib Ibrutinib is a P-gp and breast cancer resistance protein (BCRP) inhibitor in vitro. As no clinical data are available on this interaction, it cannot be excluded that ibrutinib could inhibit intestinal P-gp and BCRP after a therapeutic dose. To minimise the potential for an interaction in the GI tract, oral narrow therapeutic range, P-gp or BCRP substrates such as digoxin or methotrexate should be taken at least 6 hours before or after IMBRUVICA. Ibrutinib may also inhibit BCRP in the liver and increase the exposure of medicinal products that undergo BCRP-mediated hepatic efflux, such as rosuvastatin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) digoxin (HOS-086172) methotrexate (HOS-087522) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:30:00Z · SHA-256 a9cee31168a81381e2e0315390c7e6008548b2272679979bce5eb1784595366b · Passage 7a6d73067fdb66e50e4e73910930da48b39bc7e659ac7487d7dc7f45ec11af87 · Zeichen 4105–4786 im Abschnitt